We are live on ! Find out more
NKGN

NKGen Biotech, Inc. Common Stock
NKGN

Delisted

NKGN was delisted on the 4th of March, 2025.

Back to rankings

59 hedge funds and large institutions have $155M invested in NKGen Biotech, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 13 increasing their positions, 6 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 6

60% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 10

11% more funds holding

Funds holding: 53 → 59 (+6)

9% more capital invested

Capital invested by funds: $143M → $155M (+$12.8M)

Holders
59
Holders Change
+6
Holders Change %
+11.32%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
13
Reduced
6
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SIM
Sandia Investment Management
Massachusetts
+$6.18M
2
CIM
Cowen Investment Management
New York
+$5.43M
3
Jane Street
Jane Street
New York
+$4.95M
4
CAC
Cowen and Company
New York
+$3.59M
5
JP Morgan Chase
JP Morgan Chase
New York
+$3.3M

Top Sellers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
-$11.9M
2
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$7.33M
3
SCM
Saba Capital Management
New York
-$4.05M
4
UOC
UBS O'Connor
Illinois
-$3.12M
5
FTCM
Fir Tree Capital Management
New York
-$2.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
26
Elequin Capital
New York
$2.18M +$2.16M +218,800 New
FBCM
27
Fort Baker Capital Management
California
$2M – – –
SCM
28
Shaolin Capital Management
Florida
$1.99M -$434K -43,896 -18%
AIMCA
29
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$1.99M – – –
MTCM
30
Mint Tower Capital Management
Netherlands
$1.99M +$1.98M +200,000 New
RL
31
RPO LLC
Connecticut
$1.89M +$1.88M +190,000 New
Millennium Management
32
Millennium Management
New York
$1.55M -$893K -90,406 -37%
ACM
33
Atalaya Capital Management
New York
$1.49M – – –
OCM
34
Oaktree Capital Management
California
$995K – – –
SC
35
Sculptor Capital
New York
$995K – – –
BI
36
Bulldog Investors
New Jersey
$995K +$988K +100,000 New
GCIA
37
Gabelli & Co Investment Advisers
New York
$858K – – –
CM
38
Crestline Management
Texas
$756K +$751K +76,000 New
AA
39
AQR Arbitrage
Connecticut
$697K +$346K +35,000 +100%
Walleye Capital
40
Walleye Capital
New York
$635K +$192K +19,406 +44%
TI
41
Telemetry Investments
New York
$593K – – –
SIA
42
Schechter Investment Advisors
Michigan
$561K +$557K +56,398 New
PI
43
PEAK6 Investments
Illinois
$549K – – –
DCM
44
Difesa Capital Management
New York
$529K +$525K +53,117 New
CL
45
CSS LLC
Illinois
$525K -$1.05M -106,349 -67%
COPPSERS
46
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$498K – – –
Walleye Trading
47
Walleye Trading
New York
$358K – – –
BFM
48
Boothbay Fund Management
New York
$318K +$316K +31,992 New
SSA
49
Schonfeld Strategic Advisors
New York
$302K -$110K -11,100 -27%
GCWM
50
Graham Capital Wealth Management
District of Columbia
$281K +$279K +28,248 New
1
2
3

NKGN Hedge Fund Activity: Q4 2022 in Review

59 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q4 2022, worth a combined $155M — up 9% from $143M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new NKGN positions and 10 closed out — a net gain of 6 holders — while 13 added to existing stakes and 6 trimmed.

The largest buyer was Sandia Investment Management, opening a new position worth an estimated $6.18M. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $11.9M sold.

  • 59 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q4 2022, up from 53 in Q3 2022.
  • Funds reported $155M of NKGen Biotech, Inc. Common Stock stock for Q4 2022, up 9% quarter-over-quarter.
  • 16 funds opened new NKGen Biotech, Inc. Common Stock positions in Q4 2022 and 10 closed out, a net change of +6 holders.
  • The largest NKGen Biotech, Inc. Common Stock buyer in Q4 2022 was Sandia Investment Management, an estimated $6.18M added.
  • The largest NKGen Biotech, Inc. Common Stock seller in Q4 2022 was Highbridge Capital Management, an estimated $11.9M sold.

Based on aggregated 13F filings for Q4 2022.